Quidel Corporation (QDEL) : Eagle Boston Investment Management Inc scooped up 2,474 additional shares in Quidel Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 328,963 shares of Quidel Corporation which is valued at $7,006,912.Quidel Corporation makes up approximately 0.91% of Eagle Boston Investment Management Inc’s portfolio.
Other Hedge Funds, Including , First Mercantile Trust Co reduced its stake in QDEL by selling 310 shares or 5.64% in the most recent quarter. The Hedge Fund company now holds 5,190 shares of QDEL which is valued at $114,388. Quidel Corporation makes up approx 0.02% of First Mercantile Trust Co’s portfolio.Simplex Trading reduced its stake in QDEL by selling 26 shares or 5.01% in the most recent quarter. The Hedge Fund company now holds 493 shares of QDEL which is valued at $10,866.Bnp Paribas Arbitrage Sa boosted its stake in QDEL in the latest quarter, The investment management firm added 1,192 additional shares and now holds a total of 2,234 shares of Quidel Corporation which is valued at $48,679.
Quidel Corporation closed down -0.79 points or -3.58% at $21.3 with 81,331 shares getting traded on Tuesday. Post opening the session at $22.14, the shares hit an intraday low of $21.12 and an intraday high of $22.15 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Quidel Corporation reported $-0.11 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $-0.13. The company had revenue of $39.10 million for the quarter, compared to analysts expectations of $38.02 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.14 EPS.
Quidel Corporation is engaged in the development manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases women’s health and gastrointestinal diseases. The Company sells its products directly to end users and distributors in each case for professional use in physician offices hospitals clinical laboratories reference laboratories universities retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions including infectious diseases women’s health autoimmune diseases bone health thyroid diseases and fecal occult blood.